Last reviewed · How we verify

Estradiol transdermal three 90 μL sprays — Competitive Intelligence Brief

Estradiol transdermal three 90 μL sprays (Estradiol transdermal three 90 μL sprays) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hormone replacement therapy (HRT); estrogen. Area: Endocrinology / Women's Health.

phase 3 Hormone replacement therapy (HRT); estrogen Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ) Endocrinology / Women's Health Small molecule Live · refreshed every 30 min

Target snapshot

Estradiol transdermal three 90 μL sprays (Estradiol transdermal three 90 μL sprays) — Lumara Health, Inc.. Estradiol binds to estrogen receptors (ERα and ERβ) throughout the body to restore circulating estrogen levels in postmenopausal women.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Estradiol transdermal three 90 μL sprays TARGET Estradiol transdermal three 90 μL sprays Lumara Health, Inc. phase 3 Hormone replacement therapy (HRT); estrogen Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ)
Estradiol/norethindrone acetate Estradiol/norethindrone acetate Myovant Sciences GmbH marketed Hormone replacement therapy (HRT) Estrogen receptor alpha and beta; progesterone receptor
estradiol plus progesterone estradiol plus progesterone Peking Union Medical College Hospital marketed Hormone replacement therapy (HRT) Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ), Progesterone receptor (PR)
EVOREL® CONTI EVOREL® CONTI Royal Brompton & Harefield NHS Foundation Trust marketed Hormone replacement therapy (HRT) — combined estrogen/progestin Estrogen receptors (ER-α, ER-β) and progesterone receptor (PR)
Transdermal strogen Transdermal strogen Parc de Salut Mar marketed Hormone replacement therapy (HRT) / Estrogen replacement Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)
estradiol and progesterone estradiol and progesterone Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University marketed Hormone replacement therapy (HRT) Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ), Progesterone receptor (PR)
Femoston® 1, Femoston® 2 Femoston® 1, Femoston® 2 Scientific Research Institute of Public Health, Russian Federation marketed Hormone replacement therapy (HRT) Estrogen receptor (ER-α, ER-β) and progesterone receptor (PR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hormone replacement therapy (HRT); estrogen class)

  1. Lumara Health, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Estradiol transdermal three 90 μL sprays — Competitive Intelligence Brief. https://druglandscape.com/ci/estradiol-transdermal-three-90-l-sprays. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: